What is this event about?
|
|
Developing an effective pricing strategy is an imperative factor in the success and overall profit of a pharmaceutical product and this masterclass will over attendees the chance to work with an expert in the field to learn about current pricing strategies such as referencing and regulation across the EU with a unique focus on the current developments of the AMNOG in Germany.
The event will provide a unique opportunity to understand and analyse the effect of HTAs across Europe as well as the chance to learn how to plan and develop effective and appropriate pricing strategies.
|
Where is the event?
This Masterclass will take place in central London, UK
Who is leading this event?
Keiron Sparrowhawk, Partner, PriceSpective LLC
Keiron Sparrowhawk is a recognized global leader in drug pricing, reimbursement and market access with over 35 years industry and consulting experience. He co-founded PriceSpective in 2003 and established PriceSpective’s European office in London. He is responsible for Global Business Development and in particular the company’s growth in Europe and Ex-US markets. He has led numerous projects on pricing strategy leading to successful product launches across many therapy areas. He has in-depth knowledge of payers and international country pricing systems.
|
|
|
|
In association with
PriceSpective is a leading global value strategy consultancy, specializing in innovative strategies to define, drive and capture value for biopharmaceutical and medical technology assets. Through our unique integrated approach to value strategy we are well positioned to help our customers optimize payer strategies for pricing, reimbursement, evidence and implementation.
PriceSpective believes that there is inherent value in seeking to enhance and prolong human life through the development and marketing of pharmaceutical, medical device and biotechnology products. PriceSpective will guide our clients to develop and market products for patients who have the most urgent medical unmet need and/or who impose the highest economic burden on healthcare systems and society. In doing this we help patients, doctors and healthcare system. In addition society benefits and in recognition for the investment made, products achieve optimal prices and thus our clients are justly rewarded for their efforts.
By attending this event you will be better able to:
• Understand the facts and consequences of Germany’s AMNOG
• Debate EU policy challenges in access to medicines in Europe
• Hear from an expert in the field on pricing regulation and referencing
• Learn about the latest developments in health economics
• Discover the value of collaboration in HTA and managed entry schemes
• Network with and learn from senior industry representatives
Who would benefit?
Masterclass agenda
An effective pricing strategy requires long term planning
The Phase III trials need to be designed with the payer customer in mind The role of HTAs in Major EU Markets Which of the other HTA models is having the greatest influence in Europe?
What changes can we expect from the French and UK HTAs? Focus on Germany: Effects of the AMNOG What can we learn from the first 15 months of the AMNOG reforms in Germany?
What implications do the reforms have for Germany and other European countries? Price Regulation and Price Referencing Markets Despite the increasing importance of Health Technology Assessments most of Europe reference other countries to set their prices
Cross county referencing and parallel trade can be modelled to set floor prices and planned launch sequences Using an analytical framework to ensure we plan our pricing strategies appropriately How to put our learnings into practice
copyright ©
2024
SAE Media Group
| |